Cargando…

Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis

PURPOSE: A meta-analysis was conducted to assess the benefits and risks of aspirin for the primary prevention of cardiovascular disease and all-cause mortality events in adults with diabetes. METHODS: An extensive and systematic search was conducted in MEDLINE (via PubMed), Cinahl (via Ebsco), Scopu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Hua, Gu, Qing, Niu, Huining, Li, Xiaohua, Wang, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440957/ https://www.ncbi.nlm.nih.gov/pubmed/34539583 http://dx.doi.org/10.3389/fendo.2021.741374

Ejemplares similares

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
Publicado: (2010)

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
por: De Berardis, Giorgia, et al.
Publicado: (2009)

Aspirin for Primary Prevention of Cardiovascular Events: Meta-Analysis of Randomized Controlled Trials and Subgroup Analysis by Sex and Diabetes Status
por: Xie, Manling, et al.
Publicado: (2014)

Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis
por: Stegeman, Inge, et al.
Publicado: (2015)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Aspirin for the Primary Prevention of Cardiovascular Events: A systematic review and meta-analysis comparing patients with and without diabetes
por: Calvin, Andrew D., et al.
Publicado: (2009)

The Benefit and Safety of Aspirin for Primary Prevention of Ischemic Stroke: A Meta-Analysis of Randomized Trials
por: Lei, Hong, et al.
Publicado: (2016)

Aspirin for primary prevention of cardiovascular disease
por: Nansseu, Jobert Richie N., et al.
Publicado: (2015)

Aspirin for Primary Prevention of Cardiovascular Disease
por: Kim, Ji Hye, et al.
Publicado: (2019)

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events
por: Sylvester, Katelyn W, et al.
Publicado: (2013)

Aspirin and Its Potential Preventive Role in Cancer: An Umbrella Review
por: Song, Yongxi, et al.
Publicado: (2020)

Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention()
por: Wang, Frances M., et al.
Publicado: (2023)

Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
por: Christensen, Mikkel B., et al.
Publicado: (2021)

Aspirin overutilization for the primary prevention of cardiovascular disease
por: VanWormer, Jeffrey J, et al.
Publicado: (2014)

Aspirin for the primary prevention of cardiovascular disease in the elderly
por: O’Sullivan, Jack W
Publicado: (2019)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Coccheri, Sergio
Publicado: (2017)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
por: Chen, Yinong, et al.
Publicado: (2021)

The Efficacy And Safety Of Aspirin As The Primary Prevention Of Cardiovascular Disease: An Updated Meta-Analysis
por: Xie, Wenchao, et al.
Publicado: (2019)

Prediction and prevention of preeclampsia in women with preexisting diabetes: the role of home blood pressure, physical activity, and aspirin
por: Do, Nicoline Callesen, et al.
Publicado: (2023)

Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
por: Djatche, Laurence M., et al.
Publicado: (2018)

Should Aspirin Be Used for the Primary Prevention of Cardiovascular Disease in the General Population?
por: Huang, Qing-Yu, et al.
Publicado: (2015)

Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease—A Systematic Review and Meta-Analysis
por: Hu, Yao, et al.
Publicado: (2020)

Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China
por: Jiang, Minghuan, et al.
Publicado: (2019)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Aspirin for Primary Prevention of Cardiovascular Diseases: “WALTZ” with the Evidence
por: Dimitriadis, Kyriakos, et al.
Publicado: (2022)

Aspirin for the primary prevention of skin cancer: A meta-analysis
por: ZHU, YUN, et al.
Publicado: (2015)

Aspirin for primary prevention of stroke in individuals without cardiovascular disease—A meta-analysis
por: Judge, Conor, et al.
Publicado: (2019)

Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease
por: Haim-Pinhas, Hadar, et al.
Publicado: (2022)

Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age
por: Kim, Kyungmann, et al.
Publicado: (2021)

Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis
por: Zhao, Binghao, et al.
Publicado: (2021)

Aspirin as Primary Prevention of Acute Coronary Heart Disease Events
por: Glasser, Stephen P., et al.
Publicado: (2014)

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins
por: De Berardis, Giorgia, et al.
Publicado: (2007)

Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials
por: Seidu, Samuel, et al.
Publicado: (2019)

Aspirin for Prevention of Cardiovascular Disease
por: Mendy, Vincent L., et al.
Publicado: (2017)

Assessment of QRISK3 as a predictor of cardiovascular disease events in type 2 diabetes mellitus
por: Mu, Xiaodie, et al.
Publicado: (2022)

Impact of preexisting diabetes mellitus on cardiovascular and all-cause mortality in patients with atrial fibrillation: A meta-analysis
por: Xu, Juan, et al.
Publicado: (2022)

Low-Dose Aspirin Prevents Kidney Damage in LPS-Induced Preeclampsia by Inhibiting the WNT5A and NF-κB Signaling Pathways
por: Li, Guanlin, et al.
Publicado: (2021)

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
por: Gelbenegger, Georg, et al.
Publicado: (2019)

All-cause mortality following low-dose aspirin treatment for patients with high cardiovascular risk in remote Australian Aboriginal communities: an observational study
por: Zhao, Yuejen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ps80k2lp4h9k785gd6tg8796ni